NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
13.64
-1.67 (-10.91%)
At close: Jul 29, 2026, 4:00 PM EDT
13.91
+0.27 (1.98%)
After-hours: Jul 29, 2026, 7:49 PM EDT
NeuroPace Revenue
NeuroPace had revenue of $22.07M in the quarter ending March 31, 2026, a decrease of -2.02%. This brings the company's revenue in the last twelve months to $99.53M, up 18.06% year-over-year. In the year 2025, NeuroPace had annual revenue of $99.99M with 25.13% growth.
Revenue (ttm)
$99.53M
Revenue Growth
+18.06%
P/S Ratio
4.67
Revenue / Employee
$452,409
Employees
220
Market Cap
465.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 99.99M | 20.08M | 25.13% |
| Dec 31, 2024 | 79.91M | 14.49M | 22.14% |
| Dec 31, 2023 | 65.42M | 19.90M | 43.72% |
| Dec 31, 2022 | 45.52M | 337.00K | 0.75% |
| Dec 31, 2021 | 45.18M | 4.05M | 9.83% |
| Dec 31, 2020 | 41.14M | 4.17M | 11.27% |
| Dec 31, 2019 | 36.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 857.50M |
| Orthofix Medical | 825.37M |
| Tactile Systems Technology | 343.52M |
| Viemed Healthcare | 286.57M |
| OrthoPediatrics | 243.30M |
| Cerus | 216.56M |
| Cytek Biosciences | 204.17M |
| Pacific Biosciences of California | 160.03M |
NPCE News
- 13 hours ago - NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial - TheFly
- 1 day ago - NeuroPace Transcript: FDA announcement - Transcripts
- 1 day ago - NeuroPace Press release: FDA announcement - Filings
- 1 day ago - NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy - Business Wire
- 6 days ago - NeuroPace initiated with an Outperform at Mizuho - TheFly
- 7 weeks ago - NeuroPace Transcript: AGM 2026 - Transcripts
- 2 months ago - NeuroPace announces FDA approval of ECoG Assistant - TheFly
- 2 months ago - NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting - Business Wire